A stronger growth hormone booster than GHRP-6, with a more moderate appetite increase. It raises both GH and IGF-1 (another important growth signal), though it can slightly bump cortisol and prolactin levels.
What to Expect
Week 1–2
Appetite increase (less than GHRP-6). Improved sleep depth. Strong GH pulse post-injection. Mild cortisol and prolactin elevation.
Week 3–6
Better recovery and body composition changes. Moderate appetite stimulation sustained. Fat loss and lean mass gains beginning.
Week 8+
Meaningful body recomposition. Connective tissue benefits. More potent GH release than GHRP-6 but with more hormonal side effects.
Common Side Effects
Dosing
100-300 mcg subq 2-3 times daily on an empty stomach. Cycle for 8-12 weeks.
Benefit Profile
Medical Considerations
Contraindications
- ✕Active cancer
- ✕Pituitary tumors
- ✕Pregnancy/nursing
- ✕Uncontrolled diabetes
Drug Interactions
Recommended Monitoring
- →IGF-1 levels
- →Prolactin levels
- →Fasting glucose and HbA1c
- →Cortisol levels
This information is for educational purposes only. Always consult a qualified healthcare provider before starting any peptide protocol.
Published Research
Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.
Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp.
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.
The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
Growth hormone-releasing peptide-2 infusion synchronizes growth hormone, thyrotrophin and prolactin release in prolonged critical illness.
Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.
Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.
The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion.
Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness.